Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prenetics Global Limited (NASDAQ: PRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Prenetics files reports with the U.S. Securities and Exchange Commission under the Exchange Act, including Form 20-F for annual reporting and Form 6-K for current reports. These filings document key developments in the company’s health sciences business, its IM8 premium health and longevity brand, and its capital markets activities.
Form 6-K current reports for Prenetics frequently furnish press releases on topics such as quarterly financial results, public offerings of Class A ordinary shares and associated warrants, warrant exchange programs, strategic divestitures, and updates to capital allocation strategy. For example, 6-K filings have incorporated press releases announcing third quarter financial results, the closing of a best efforts public offering, and the cessation of new Bitcoin purchases in favor of focusing capital on IM8.
Filings also disclose capital structure details, including the terms of Class A, Class B, and Class C warrants, placement agency agreements, and warrant agency agreements. These documents provide the legal and economic terms governing warrants, exercise prices, durations, and any forced-redemption features. Investors interested in potential dilution, warrant overhang, and equity-linked instruments can review these filings to understand how Prenetics manages its capital structure.
SEC reports further capture strategic and governance events, such as notices of annual general meetings, incorporation by reference of press releases into registration statements on Form F-3 and Form S-8, and information about principal executive office locations in Charlotte, North Carolina, and Hong Kong. Certain 6-Ks also describe open market share purchases by members of the executive leadership team, offering insight into insider activity and alignment with shareholders.
On Stock Titan, these filings are updated as they are released on EDGAR. AI-powered summaries help explain the significance of complex documents, including annual reports on Form 20-F, quarterly results furnished on Form 6-K, and filings related to offerings and warrant exchanges. Users can quickly see what changed in a filing, how it affects Prenetics’ IM8-focused strategy, and where insider transactions or capital allocation decisions appear in the official record.
By reviewing Prenetics’ SEC filings alongside AI-generated insights, investors can better understand the company’s financial reporting, risk disclosures, capital allocation policies, and structural changes that shape the long-term outlook for PRE and its IM8 health and longevity platform.
Prenetics Global Limited plans to fully divest its treasury holdings of approximately 510 Bitcoin, targeting completion by May 14, 2026. Based on recent prices of about $80,000 per BTC, the company currently expects gross proceeds of roughly $40 million.
After the sale, Prenetics expects total cash, current financial assets and escrowed consideration to increase from about $112 million as of March 31, 2026 to approximately $145 million to $150 million, with no indebtedness. The Board has adopted a policy not to purchase Bitcoin or other digital assets going forward, focusing capital on the IM8 consumer health business, which is targeting $180 million to $200 million in FY2026 revenue.
The company intends to use divestment proceeds to potentially expand its up to $40 million share repurchase program, accelerate IM8 marketing, fund new product launches in Q4 2026 and support international expansion across more than 40 countries. Prenetics expects to report selected Q1 FY2026 results on May 14, 2026, when it also plans to disclose final Bitcoin sale proceeds and volume-weighted average price.
Prenetics Global Limited, a Cayman Islands holding company with operations primarily in Hong Kong, files its annual report describing its structure, risks and recent strategic shifts. As of December 31, 2025, it had 16,874,089 ordinary shares outstanding, including 15,293,117 Class A and 1,580,972 Class B shares, and 17,352,363 warrants.
The company reports net losses of $64.8 million, $49.8 million and $38.7 million for 2023, 2024 and 2025, reflecting heavy investment in marketing and growth. Selling and marketing expenses were $35.5 million in 2025, equal to 38.5% of revenue from continuing operations, as Prenetics builds its CircleDNA and IM8 consumer health brands.
Prenetics highlights legal and regulatory risks tied to operating in Hong Kong as a Special Administrative Region of China, including potential future application of PRC data and cybersecurity rules and evolving U.S.-China relations. It also discloses holding about 510 Bitcoin as a long-term treasury reserve, noting price volatility, regulatory uncertainty and custody risks that could materially affect its balance sheet and earnings under IFRS revaluation accounting.
Prenetics Global Ltd ownership update: Genetel Bioventures Ltd and Michael Yang Mengsu report beneficial ownership of 488,857 Class A Ordinary Shares, representing 3.3% of the Class A shares outstanding. The percentage is calculated on an aggregate of 14,697,463 Class A Ordinary Shares outstanding as of March 31, 2026.
The statement is filed by Genetel and Mr. Yang Mengsu and clarifies voting and dispositive powers shown on the cover page. Signatures on the amendment are dated April 22, 2025.
Prenetics Global Limited announced a multi-year global partnership with NBA champion and two-time MVP Giannis Antetokounmpo, who becomes a global partner of IM8 and a shareholder in Prenetics. This aligns his 35 million-plus social followers with IM8’s growth strategy across the United States, Europe, Africa, and Asia.
IM8, co-founded with David Beckham, has rapidly scaled since its December 2024 launch, reaching $100 million in annualized recurring revenue in 11 months, more than 22 million servings delivered and about 750,000 customer purchases in 31 countries. The brand is projected to generate approximately $180–$200 million in revenue in 2026.
Management highlights strong alignment with athlete-partners, all of whom hold equity, and notes up to $42.75 million in combined corporate and personal share commitments. Prenetics reports approximately $160 million of adjusted liquidity and zero debt as of March 1, 2026, with adjusted EBITDA profitability targeted by Q4 2027.
Prenetics Global Limited registers for resale 2,360,416 Class A Ordinary Shares issuable upon exercise of Exchange Warrants. The resale registration covers shares held by selling shareholders and the company will not receive proceeds from resale, although it may receive proceeds if the Exchange Warrants are exercised for cash. Shares outstanding were 14,697,463 Class A Ordinary Shares as of March 31, 2026.
The Exchange Warrants were issued in connection with prior warrant exchanges and become exercisable upon effectiveness of this registration statement; each warrant has an $18.00 exercise price and a two-year term from first exercisability.
Prenetics Global Ltd director Darshan Ravindra Shah filed an initial ownership statement showing equity interests in the company. He holds 5,599 Restricted Stock Units, each representing a right to receive one Class A Ordinary Share, which vest on February 15, 2027 under the 2022 Share Incentive Plan.
Following this filing, he also holds 4,506 Class A Ordinary Shares directly. The RSUs are scheduled to be settled and delivered in shares upon vesting, with the award expiring on February 16, 2032.
Prenetics Global Ltd director and Chief Executive Officer Danny Sheng Wu Yeung has reported his initial ownership on a Form 3. He directly holds 933,380 Class B Ordinary Shares and 138,694 Class A Ordinary Shares. He also has indirect ownership of 647,592 Class B Ordinary Shares through Da Yeung Limited, a company he wholly owns.
Yeung additionally holds Restricted Stock Units representing 53,953 underlying Class B Ordinary Shares at an exercise price of $0.0001 per share, expiring on June 23, 2030. These RSUs were granted under the 2022 Share Incentive Plan and vest in scheduled tranches during 2026, with settlement of vested RSUs in Ordinary or Class A shares at his election.
Prenetics Global Ltd director Cheng Yin Pan filed an initial ownership report showing indirect holdings through M13 Capital Management Holdings Limited. The filing lists 75,021 Class A Ordinary Shares and 15,873 Restricted Stock Units, each RSU representing one Class A Ordinary Share vesting on May 17, 2026.
Prenetics Global Ltd Chief Financial Officer Hoi Chun Lo reported his initial equity holdings. He directly owns 487,462 Class A Ordinary Shares and two groups of Restricted Stock Units that can convert into 15,272 and 32,736 Class A Ordinary Shares at nominal exercise prices, with vesting in 2026 and expirations in 2030 and 2032.
Prenetics Global Ltd director David Vanderveen filed an initial ownership report showing his equity holdings. He directly holds 38,305 Class A Ordinary Shares and an additional 1,648 Class A Ordinary Shares are held indirectly by his spouse. He also holds 8,681 Restricted Stock Units granted under the 2022 Share Incentive Plan, each representing one Class A Ordinary Share. These RSUs vest on June 15, 2026, subject to continued service, and will be settled in shares upon vesting.